Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie is investing $195m to strengthen domestic active pharmaceutical ingredient (API) production within the US, with the ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

AbbVie, the maker of Botox, Humira, and Rinvoq, will invest $195 million to expand its North Chicago manufacturing facility, ...

US pharma major AbbVie yesterday announced a $195 million investment in its North Chicago, Illinois manufacturing plant to ...

AbbVie, a global leader in life sciences, announced Tuesday the company’s is investing $195 million to expand its North ...

AbbVie (NYSE:ABBV) invests $195M in North Chicago for API production, boosting U.S. pharmaceutical manufacturing. Read more ...

Drugmaker AbbVie plans to construct a $195 million facility near its headquarters in North Chicago to manufacture active pharmaceutical ingredients, The Chicago Tribune reported Aug. 12. Construction ...

As pharma companies big and small play up their U.S. investment plans during the second Trump administration, the particulars ...

AbbVie has shared promising top-line results from a late-stage study of its JAK inhibitor Rinvoq (upadacitinib) in severe ...